The CCNB3 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the CCNB3 gene. This product provides a genetically disrupted model of cyclin B3 in the near-haploid HAP1 cell line, enabling investigation of its roles in cell cycle regulation and mitotic progression without the need for single-cell clonal isolation. The polyclonal format maintains a heterogeneous pool of edited alleles, offering a robust system for functional genomics and pathway interrogation.
The HAP1 cell line is a near-haploid human cell line derived from the chronic myeloid leukemia cell line KBM-7. It exhibits an adherent fibroblast-like morphology and contains a single copy of most chromosomes, which simplifies gene editing and phenotypic analysis. Its hematopoietic origin and haploid state make HAP1 an attractive model for genetic knockout studies, particularly in cancer biology and drug discovery. The cell line is widely used for high-throughput screening and mechanistic studies due to its ease of genetic manipulation and well-characterized growth properties.
CCNB3 encodes cyclin B3, a key regulator of the G2/M transition and mitotic entry. Cyclin B3 binds and inhibits CDK2, and also interacts with CDK1 and the cofactor Cks1. It is transcriptionally regulated by E2F and FOXO transcription factors, and its activity is modulated by p53 and CDK inhibitors. Downstream, CCNB3 influences mitotic spindle assembly and spindle checkpoint function, involving components such as PLK1, Aurora kinases, and the spindle assembly checkpoint proteins BUB1 and MAD2. Disruption of CCNB3 is predicted to impair cell cycle progression and compromise mitotic checkpoint integrity.
In the HAP1 cellular context, CCNB3 knockout provides a powerful model to dissect cell cycle checkpoints and mitotic dynamics. The near-haploid background sensitizes cells to perturbations in mitotic regulators, making this model particularly useful for studying synthetic lethality and drug responses. Given the involvement of CCNB3 in malignancies such as BCOR-CCNB3 sarcoma, breast cancer, and lung cancer, these knockout cells serve as a valuable tool for oncology research, enabling the identification of vulnerabilities in cyclin B3-dependent cancers.
Researchers can employ these polyclonal knockout cells in a variety of assays, including Western blotting for cyclin B3 and cell cycle markers, flow cytometry for DNA content analysis, immunofluorescence to assess mitotic spindle morphology, colony formation assays, drug sensitivity profiling, and RNA-seq transcriptomics. The model supports functional genomics, drug target validation, synthetic lethality screening, and mitotic checkpoint studies. For additional technical specifications or ordering details, please contact Ascent Research.
